智通财经APP讯，海吉亚医疗(06078)公布，2025年12月22日耗资53.295万港元回购4.18万股股份。 ...

海吉亚医疗(06078)公布，2025年12月22日耗资53.295万港元回购4.18万股股份。 ...

表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 海吉亞醫療控股有限公司 呈交日期： 2025年12月22日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06078 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Group 1 - The "Annual Outstanding Healthcare Enterprises" award recognizes companies in the Chinese healthcare industry that excel in innovation, technological leadership, market influence, social value, and sustainable development [4] - The award winners include Alibaba Health (00241.HK), Anxuyuan, Baize Medical (02609.HK), Gushengtang (02273.HK), Haijia Medical (06078.HK), Jinhua Medical Group (01110.HK), Kangchen Pharmaceutical (01681.HK), Ping An Good Doctor (01833.HK), Weitai Medical-B (02235.HK), and Xinwei Medical-B (06609.HK) [1] - The selection process involved quantitative data analysis and an expert review panel to determine the final results [4] Group 2 - The "Jin Ge Award" aims to create a reference for the investment community by highlighting the most valuable listed companies and unicorns in China [4] - The evaluation covers all listed companies and unicorns on the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, American Stock Exchange, and NASDAQ [4]

Core Viewpoint - The company, Haijia Medical, announced a share buyback program due to its stock price not reflecting its intrinsic value or business prospects, committing to repurchase shares for at least RMB 300 million [1] Group 1: Share Buyback Announcement - On December 15, Haijia Medical disclosed its intention to buy back shares, stating that the current trading price does not reflect its intrinsic value [1] - The company executed its first buyback on December 17, purchasing approximately 493,800 shares for about HKD 6.0098 million [1] Group 2: Market Performance and Sentiment - On December 12, Haijia Medical's stock hit a year-low of HKD 11.33, indicating a downward trend away from the 5-day moving average [3] - Following the buyback announcement, the stock price rose by 3.27% on December 16, although it showed signs of selling pressure with a significant increase in trading volume [6][9] - The trading volume on December 16 surged to 11.5494 million shares, a 152.05% increase from the previous day, indicating a shift in market sentiment [6] Group 3: Financial Performance and Valuation - Haijia Medical's mid-year report indicated a decline in revenue from inpatient services by 18.4% year-on-year, while outpatient services saw a decrease of 11.2% [10] - The company reported stable patient visits at 2.2 million, suggesting that demand for its services remains unaffected despite revenue fluctuations [10] - The company's capital expenditure has decreased by 28.5% to RMB 242 million, indicating a shift towards mergers and acquisitions rather than new hospital constructions [11] Group 4: Valuation Comparison - Haijia Medical's price-to-earnings (PE) ratio stands at 15.71, which is below the industry average of 17, suggesting that the company is undervalued compared to its peers [12]

Core Viewpoint - The company, Haijia Medical, announced a share buyback program due to its stock price not reflecting its intrinsic value or business prospects, committing to repurchase shares for at least RMB 300 million [1]. Group 1: Share Buyback Announcement - On December 15, Haijia Medical disclosed its intention to buy back shares, stating that the current trading price does not reflect its intrinsic value [1]. - The company executed its first buyback on December 17, purchasing approximately 493,800 shares for about HKD 6.0098 million [1]. Group 2: Market Performance Analysis - On December 12, Haijia Medical's stock hit a year-low of HKD 11.33, indicating a downward trend away from the 5-day moving average [3]. - Since August 1, the stock has been in a downtrend, with a significant drop following a profit warning, leading to low trading volumes [3][5]. - The stock's highest price on December 12 was HKD 11.61, which was below the lower Bollinger Band of HKD 11.64, indicating an oversold condition [3]. Group 3: Trading Volume and Market Sentiment - Following the buyback announcement, trading volume increased significantly, with a notable rise in daily average volume, indicating a shift in market sentiment [5][8]. - On December 16, the stock rose by 3.27% but showed signs of selling pressure, with trading volume increasing by 152.05% compared to the previous day [5][6]. Group 4: Financial Performance and Valuation - Haijia Medical's mid-year report indicated a decline in revenue for inpatient and outpatient services, with inpatient revenue at RMB 1.22 billion (down 18.4% year-on-year) and outpatient revenue at RMB 722 million (down 11.2% year-on-year) [9]. - The company reported stable patient visits at 2.2 million, suggesting demand for its services remains unaffected despite revenue declines [9]. - The company is optimizing capital allocation, with a decrease in capital expenditures to RMB 242 million, down 28.5% year-on-year, and plans to focus on acquisitions rather than new hospital constructions [10]. Group 5: Industry Valuation Context - Haijia Medical's price-to-earnings (PE) ratio stands at 15.71, significantly lower than the industry average of 17, indicating a potential undervaluation compared to peers [11].

每经AI快讯，海吉亚医疗(06078.HK)再涨超4%，截至发稿涨3.53%，报12.6港元，成交额4077.82万港 元。 ...

消息面上，海吉亚医疗公布，12月17日，公司耗资约600.98万港元回购49.38万股股份。据悉，海吉亚医 疗本月15日公告，将动用回购授权，以不时在公开市场上以不少于人民币3亿元的总价格回购本公司股 份。 海吉亚医疗(06078)再涨超4%，截至发稿，涨3.53%，报12.6港元，成交额4077.82万港元。 交银国际此前表示，随着控费压力释放、落后产能出清，民营医疗机构有望重回较快增长通道。推荐短 期业绩反弹可期、长期扩张路径清晰的优质标的，如海吉亚医疗等。 ...

Group 1 - The core viewpoint of the article highlights that Haijia Medical (06078) has seen a stock price increase of over 4%, currently trading at 12.6 HKD with a transaction volume of 40.78 million HKD [1] - Haijia Medical announced a share buyback of approximately 6.0098 million HKD for 493,800 shares, indicating a strategic move to enhance shareholder value [1] - The company plans to utilize its buyback authorization to repurchase shares in the open market for a total price of no less than 300 million RMB [1] Group 2 - According to CMB International, the pressure on cost control is easing, and the elimination of outdated production capacity is expected to allow private medical institutions to return to a faster growth trajectory [1] - CMB International recommends high-quality stocks like Haijia Medical, which are expected to see a rebound in short-term performance and have a clear long-term expansion path [1]

海吉亚医疗(06078)公布，2025年12月17日耗资约600.98万港元回购49.38万股股份。 ...